Van Scoter indicated the company is "on track for commissioning of the [sulfide electrolyte production] line in 2026." Management stated they are focused on "ramp electrolyte sampling and identify ...
- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: ...
CHARLESTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today outlined ...
Solid Power (ticker: SP), a leader in solid-state battery technology, provided a comprehensive update on its business progress and financial results for the first quarter of 2024. The company reported ...
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback